REYKJAVIK, Iceland-Pharmaceutical company Hoffman-La Roche will try to develop a schizophrenia drug based on information from the Icelandic gene pool.
A research project done by deCODE genetics in Iceland has been using the entire Icelandic population as a study subject. Kari Stefansson, deCODE CEO, said the majority of the country's 270,000 people have been included in the DNA database.
Roche agreed to pay the company $200 million for information gathered from the country's DNA. Since the deal was signed in February 1998, deCode has found genes related to eight different diseases.
The schizophrenia gene encodes a protein that appears to be involved with the disease itself. Another protein that interacts with the one made by the gene may also provide a target for a drug.
Schizophrenia affects 1% of the global population and usually appears during adolescence or young adulthood. Drugs can currently control hallucinations, delusions, and emotional disturbances caused by the disease.
Information from www.arizonarepublic.com
Gag Order Puts Public Health at Risk, APIC Urges Immediate Action
February 4th 2025APIC warns that the HHS gag order on CDC communications endangers public health, delaying critical infection updates and weakening outbreak response amid rising tuberculosis, avian flu, Ebola, and measles threats.
Breaking Barriers: The Future of HIV Prevention and the Fight for Widespread PrEP Access
January 31st 2025Despite medical advances, HIV prevention faces roadblocks—low PrEP adoption, stigma, and accessibility issues threaten progress. Experts push for innovative, long-acting solutions to end the epidemic.
The Hidden Dangers of Hospital Ventilation: Are We Spreading Viruses Further?
January 31st 2025New research reveals hospital ventilation and air purifiers may unintentionally spread viral particles, increasing infection risks. Infection preventionists must rethink airflow strategies to protect patients and staff.